Founded in 2013 Peregrine Ophthalmic Pte Ltd is a privately-held company based in Singapore.
Our flagship product is liposomal latanoprost, the first nanomedicine product in ophthalmology. It is a licensed technology from the Singapore Eye Research Institute and Nanyang Technological University. Liposomal latanoprost is a sustained release product of Latanoprost for the medical treatment of glaucoma. A single dose of liposomal latanoprost has been shown to maintain a consistent and clinically significant IOP lowering effect over several months. Liposomal latanoprost is easily delivered in the clinic by the ophthalmologist, and is extremely well tolerated by patients. Peregrine Ophthalmic has obtained FDA approval to conduct clinical trials in the USA with liposomal latanoprost. Phase 2 multi-centre clinical trials are now underway.
To deliver new solutions for the successful medical management of glaucoma and other eye diseases.
Combining 50 years of experience in materials science and technology with our in-depth expertise of ophthalmology to develop proprietary drug delivery systems for the eye.